- Report
- March 2024
- 185 Pages
Global
From €3259EUR$3,374USD£2,789GBP
€3621EUR$3,749USD£3,099GBP
- Report
- March 2024
- 186 Pages
Global
From €3259EUR$3,374USD£2,789GBP
€3621EUR$3,749USD£3,099GBP
- Report
- December 2023
- 120 Pages
Global
From €5747EUR$5,950USD£4,918GBP
- Report
- February 2024
- 175 Pages
Global
From €4829EUR$5,000USD£4,132GBP
- Report
- November 2023
- 146 Pages
Global
From €2414EUR$2,499USD£2,065GBP
- Report
- October 2023
- 181 Pages
Global
From €4732EUR$4,900USD£4,050GBP
- Report
- February 2024
- 175 Pages
Global
From €2415EUR$2,500USD£2,066GBP
- Report
- April 2024
- 196 Pages
Global
From €4781EUR$4,950USD£4,091GBP
- Report
- February 2024
- 255 Pages
Global
From €4781EUR$4,950USD£4,091GBP
- Report
- February 2024
- 175 Pages
Global
From €4829EUR$5,000USD£4,132GBP
- Report
- February 2024
- 178 Pages
Global
From €4732EUR$4,900USD£4,050GBP
- Report
- June 2023
- 112 Pages
Global
From €4732EUR$4,900USD£4,050GBP
- Report
- February 2024
- 305 Pages
Global
From €3509EUR$3,633USD£3,003GBP
€5013EUR$5,190USD£4,290GBP
- Report
- March 2021
- 196 Pages
Global
From €4829EUR$5,000USD£4,132GBP
- Report
- April 2023
- 135 Pages
Global
From €5312EUR$5,500USD£4,546GBP
- Report
- February 2023
- 287 Pages
Global
From €5312EUR$5,500USD£4,546GBP
- Report
- November 2018
- 116 Pages
Global
From €1328EUR$1,375USD£1,136GBP
€2656EUR$2,750USD£2,273GBP
- Report
- March 2023
- 134 Pages
Global
From €5747EUR$5,950USD£4,918GBP
- Report
- October 2023
- 89 Pages
Canada
From €3380EUR$3,500USD£2,893GBP
- Report
- April 2021
- 121 Pages
Middle East, Africa
From €2028EUR$2,100USD£1,736GBP
€2897EUR$3,000USD£2,479GBP
A neurological biomarker is a biological indicator of a neurological disorder or disease. It is used to diagnose, monitor, and predict the progression of neurological diseases. Neurological biomarkers can be found in a variety of biological samples, such as blood, cerebrospinal fluid, and tissue. They can also be used to measure the effectiveness of treatments.
Neurological biomarkers are becoming increasingly important in the field of personalized medicine, as they can provide a more accurate diagnosis and prognosis of neurological diseases. They can also be used to identify potential drug targets and to monitor the progression of neurological diseases.
The neurological biomarker market is growing rapidly, driven by the increasing prevalence of neurological diseases, the development of new technologies, and the increasing demand for personalized medicine. The market is expected to continue to grow in the coming years, as more companies enter the market and develop new technologies.
Some of the major companies in the neurological biomarker market include Bio-Rad Laboratories, Inc., BioMérieux SA, Abbott Laboratories, Roche Diagnostics, and Siemens Healthineers. Show Less Read more